Responses
Clinical/translational cancer immunotherapy
Original research
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Compose a Response to This Article
Other responses
No responses have been published for this article.
